Ozyazgan Sibel, Kutluata Nilüfer, Afşar Selim, Ozdaş Sule Beyhan, Akkan Ahmet Gökhan
Department of Pharmacology and Clinical Pharmacology, Istanbul University, Cerrahpasa Faculty of Medicine, Istanbul, Turkey.
Pharmacology. 2005 Jun;74(3):119-26. doi: 10.1159/000084277. Epub 2005 Mar 3.
We investigated the vascular effects of glucagon-like peptide-1 (GLP-1) and Exendin-4 in type 2 diabetic rat aortae. Studies were performed in a normal control group (NC) (0.2 ml i.p. saline, n = 10), streptozotocin (STZ)/nicotinamide diabetic control group (DC) (a single dose of 80 mg/kg STZ i.p. injection 15 min after administration of 230 mg/kg nicotinamide i.p.), GLP-1 (GLPC) control group (1 microg/kg twice daily i.p. for 1 month, n = 10), Exendin-4 control group (EXC) (0.1 microg/kg twice daily i.p. for 1 month, n = 10), GLP-1-treated diabetic group (GLPT) (1 microg/kg twice daily i.p. for 1 month, n = 10), and Exendin-4-treated diabetic group (EXT) (0.1 microg/kg twice daily i.p. for 1 month, n = 10). One month of GLP-1 and Exendin-4 treatment significantly decreased the blood glucose levels of diabetic rats (113 +/- 2 mg/dl, p < 0.001, and 117 +/- 1 mg/dl, p < 0.001, respectively versus 181 +/- 9 mg/dl in the DC group). Sensitivity (pD2) and maximum response (% Max. Relax) of acetylcholine-stimulated relaxations in the DC group (pD2: 6.73 +/- 0.12 and 55 +/- 6, respectively) were decreased compared with the non-diabetic NC group (pD2: 7.41 +/- 0.25, p < 0.05, and 87 +/- 4, p < 0.01). Treating diabetic rats with GLP-1, pD2 values and with Exendin-4, Max. Relax %values of aortic strips to acetylcholine returned to near non-diabetic NC values (pD2: 7.47 +/- 0.15, p < 0.05, and 87 +/- 3, p < 0.01, respectively). Maximal contractile responses (Emax) to noradrenaline in aortic strips from the diabetic DC group (341 +/- 27 mg tension/mg wet weight) were significantly decreased compared with the non-diabetic NC (540 +/- 66 mg tension/mg wet weight, p < 0.001) and the GLPT group (490 +/- 25 mg tension/mg wet weight, p < 0.05). There were no significant differences in pD2 values of aortic strips to noradrenaline from all groups. Emax to KCl in aortic strips from the DC group (247 +/- 10 mg tension/mg wet weight, p < 0.01) was significantly decreased compared with non-diabetic NC group (327 +/- 26 mg tension/mg wet weight). Treating diabetic rats with GLP-1 (GLPT), Emax values of aortic strips to KCl returned to near non-diabetic NC values (271 +/- 12 mg tension/mg wet weight). GLP-1 and (partially) Exendin-4 treatment could improve the increased blood glucose level and normalize the altered vascular tone in type 2 diabetic rats.
我们研究了胰高血糖素样肽 -1(GLP -1)和艾塞那肽 -4对2型糖尿病大鼠主动脉的血管效应。实验在正常对照组(NC)(腹腔注射0.2 ml生理盐水,n = 10)、链脲佐菌素(STZ)/烟酰胺糖尿病对照组(DC)(腹腔注射230 mg/kg烟酰胺15分钟后,腹腔注射单剂量80 mg/kg STZ)、GLP -1对照组(GLPC)(每天腹腔注射两次,每次1 μg/kg,共1个月,n = 10)、艾塞那肽 -4对照组(EXC)(每天腹腔注射两次,每次0.1 μg/kg,共1个月,n = 10)、GLP -1治疗糖尿病组(GLPT)(每天腹腔注射两次,每次1 μg/kg,共1个月,n = 10)和艾塞那肽 -4治疗糖尿病组(EXT)(每天腹腔注射两次,每次0.1 μg/kg,共1个月,n = 10)中进行。GLP -1和艾塞那肽 -4治疗1个月后,糖尿病大鼠的血糖水平显著降低(分别为113±2 mg/dl,p < 0.001和117±1 mg/dl,p < 0.001,与DC组的181±9 mg/dl相比)。与非糖尿病NC组相比,DC组乙酰胆碱刺激的舒张反应的敏感性(pD2)和最大反应(%最大舒张)降低(pD2:分别为6.73±0.12和55±6)(NC组pD2:7.41±0.25,p < 0.05;%最大舒张:87±4,p < 0.01)。用GLP -1治疗糖尿病大鼠,主动脉条对乙酰胆碱的pD2值恢复到接近非糖尿病NC组的值(pD2:7.47±0.15,p < 0.05);用艾塞那肽 -4治疗,主动脉条对乙酰胆碱的最大舒张%值恢复到接近非糖尿病NC组的值(87±3,p < 0.01)。糖尿病DC组主动脉条对去甲肾上腺素的最大收缩反应(Emax)(341±27 mg张力/mg湿重)与非糖尿病NC组(540±66 mg张力/mg湿重,p < 0.001)和GLPT组(490±25 mg张力/mg湿重,p < 0.05)相比显著降低。所有组主动脉条对去甲肾上腺素的pD2值无显著差异。DC组主动脉条对氯化钾的Emax(247±10 mg张力/mg湿重,p < 0.01)与非糖尿病NC组(327±26 mg张力/mg湿重)相比显著降低。用GLP -1治疗糖尿病大鼠(GLPT),主动脉条对氯化钾的Emax值恢复到接近非糖尿病NC组的值(271±12 mg张力/mg湿重)。GLP -1和(部分)艾塞那肽 -4治疗可改善2型糖尿病大鼠升高的血糖水平,并使改变的血管张力恢复正常。